Sarah Bricault
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Sarah Bricault has a total of 42 co-authors. Here are the top co-authors by number of shared publications:
- Alan Jasanoff
Department of Biological Engineering, Massachusetts Institute of Technology, Cambridge, MA, USA
3 shared publications - Miranda Dawson
Department of Biological Engineering, Massachusetts Institute of Technology, Cambridge, USA
3 shared publications Takashi Kaise
Department of Biological Engineering, Massachusetts Institute of Technology, Cambridge, MA, USA
2 shared publicationsAgata Wisniowska
Harvard-MIT Health Sciences & Technology, Massachusetts Institute of Technology, Cambridge, USA
1 shared publication- Andrew Becker
Department of Biological Engineering, Massachusetts Institute of Technology, Cambridge, US
1 shared publication - Braeden A. Mair
Athinoula A. Martinos Center for Biomedical Imaging, Department of Radiology, Massachusetts General Hospital, Harvard Medical School, Charlestown, MA 02129, USA
1 shared publication
Latest Publications
- 13 May 2026
- Published by Springer Nature in Nature Biomedical Engineering
Liposomal nanoprobes actuated by engineered water channels for sensitive detection of molecular targets by MRI
Monitoring biochemical processes requires tools to detect specific molecular species in vivo. Although responsive probes detectable by MRI enable this, conventional MRI contrast agents often lack sufficient sensitivity. Here we circumvent this limitation using nanoscale probes constructed from pore-forming peptides incorporated into paramagnetic liposomes. In our design, target molecules control MRI contrast by regulating water access to liposome-encapsulated gadolinium chelators. The large ratio of gadolinium complexes to pores provides a sensitivity gain by over an order of magnitude compared with small-molecule MRI sensors. We demonstrate the probe architecture using biotin as a model analyte and gramicidin A as the basis for responsive pores. We then validate the biotin-sensitive liposomal probes in vitro and in rat brain, and we show that minimally invasive delivery to multiple tissue types is feasible. Furthermore, we identify pore sequences that provide greater MRI contrast effects than native gramicidin and we demonstrate that further channel modifications permit detection of different target molecules. This work thus introduces a potent and engineerable technology for molecular imaging in living systems.
- 13 May 2026
- Published by Springer Nature in Nature Biomedical Engineering
Liposomal nanoprobes actuated by engineered water channels for sensitive detection of molecular targets by MRI
Monitoring biochemical processes requires tools to detect specific molecular species in vivo. Although responsive probes detectable by MRI enable this, conventional MRI contrast agents often lack sufficient sensitivity. Here we circumvent this limitation using nanoscale probes constructed from pore-forming peptides incorporated into paramagnetic liposomes. In our design, target molecules control MRI contrast by regulating water access to liposome-encapsulated gadolinium chelators. The large ratio of gadolinium complexes to pores provides a sensitivity gain by over an order of magnitude compared with small-molecule MRI sensors. We demonstrate the probe architecture using biotin as a model analyte and gramicidin A as the basis for responsive pores. We then validate the biotin-sensitive liposomal probes in vitro and in rat brain, and we show that minimally invasive delivery to multiple tissue types is feasible. Furthermore, we identify pore sequences that provide greater MRI contrast effects than native gramicidin and we demonstrate that further channel modifications permit detection of different target molecules. This work thus introduces a potent and engineerable technology for molecular imaging in living systems.
- Open Access
- 4 April 2026
- Published by Springer Nature in Communications Biology
- Vol. 9 (1)
Quantitative comparison of methods for widespread delivery of small molecules across the blood-brain barrier
Achieving widespread delivery of pharmacological agents beyond the blood-brain barrier (BBB) remains a formidable challenge in preclinical and clinical research. Here we quantitatively evaluate and compare three strategies for brain-wide delivery that employ transient BBB disruption or infusion via the cerebrospinal fluid (CSF) in rats. Using molecular magnetic resonance imaging (MRI) techniques, we find that the three techniques produce spatially differentiated labeling patterns, with the most homogeneous delivery produced either using chemically mediated or unfocused ultrasound-based BBB manipulation methods. Contrast enhancement distributions are similar following chemical and ultrasound procedures, but differ notably from the results of intra-CSF infusion. Delivery efficiency using the two BBB disruption methods also correlates inversely with a marker of tight junction density, suggesting that common factors determine susceptibility to these techniques. Our study thus documents the spatial variation of BBB properties across the brain while offering guidance about brain-wide application of molecular technologies in neuroscience and neuromedicine.
- 4 April 2026
- Published by Springer Nature in Communications Biology
- Vol. 9 (1)
Open AccessQuantitative comparison of methods for widespread delivery of small molecules across the blood-brain barrier
Achieving widespread delivery of pharmacological agents beyond the blood-brain barrier (BBB) remains a formidable challenge in preclinical and clinical research. Here we quantitatively evaluate and compare three strategies for brain-wide delivery that employ transient BBB disruption or infusion via the cerebrospinal fluid (CSF) in rats. Using molecular magnetic resonance imaging (MRI) techniques, we find that the three techniques produce spatially differentiated labeling patterns, with the most homogeneous delivery produced either using chemically mediated or unfocused ultrasound-based BBB manipulation methods. Contrast enhancement distributions are similar following chemical and ultrasound procedures, but differ notably from the results of intra-CSF infusion. Delivery efficiency using the two BBB disruption methods also correlates inversely with a marker of tight junction density, suggesting that common factors determine susceptibility to these techniques. Our study thus documents the spatial variation of BBB properties across the brain while offering guidance about brain-wide application of molecular technologies in neuroscience and neuromedicine.
- Open Access
- 28 November 2025
- Published by MDPI AG in Pharmaceuticals
- Vol. 18 (12) , 1816
Toward Brain NaV1.8 Imaging with [11C]Suzetrigine
Background/Objective: Acute and chronic pain affect millions of individuals, yet there are currently no molecular imaging tools to directly assess pain-related mechanisms in the central nervous system (CNS). The voltage-gated sodium channel NaV1.8 plays a pivotal role in neuropathic pain by increasing the excitability of nociceptive neurons following nerve injury or inflammation. In this work, we aimed to develop a novel positron emission tomography (PET) imaging probe for NaV1.8 to facilitate noninvasive quantification of this target in the CNS and thereby advance our understanding of pain neurobiology. Methods: We selected the compound suzetrigine, a U.S. FDA-approved, highly selective non-opioid NaV1.8 inhibitor, as the first candidate for a NaV1.8-targeted PET tracer. The compound was first assessed using in silico docking and CNS multiparameter optimization (MPO) analysis to evaluate target binding and predicted brain penetrability. Radiolabeling was accomplished by O-methylation with [11C]methyl iodide to yield [11C]suzetrigine without structural modification. The tracer was then evaluated using in vitro binding assays, including autoradiography and saturation binding on rat brain tissues, to determine binding parameters (KD, Bmax), and using in vivo PET imaging in rats to assess brain uptake, time–activity curves (TACs), and tracer behavior under baseline and pretreatment conditions. Pretreatment was performed with unlabeled suzetrigine, the P-glycoprotein (P-gp) inhibitor verapamil, and the heterologous NaV1.8 inhibitor A-803467. Results: In silico docking demonstrated favorable binding of suzetrigine to the NaV1.8 active site, and the calculated CNS MPO score (>3.5) suggested adequate brain penetration. Radiochemical synthesis of [11C]suzetrigine via O-methylation yielded a high decay-corrected radiochemical yield (19.2 ± 2.7%, n = 3), excellent purity (>98%, n = 3), and moderate molar activity (62.9 ± 51.8 MBq/nmol, n = 3). Autoradiography on rat brain tissue confirmed saturable and selective binding of [11C]suzetrigine to NaV1.8. Saturation binding assays revealed a Bmax = 93 fmol/mg and a KD = 0.1 nM, supporting the imageability of NaV1.8 in the brain using this tracer. In vivo PET imaging in rats demonstrated rapid and sufficient brain uptake but revealed unexpected tracer behavior: signal intensity markedly increased following pretreatment with either unlabeled suzetrigine or the P-gp inhibitor verapamil, and showed a slight increase after pretreatment with the heterologous NaV1.8 inhibitor A-803467. Detailed analysis of PET images, TACs, and normalized area-under-curve (AUC) values indicated that these atypical uptake patterns were primarily attributable to P-gp-mediated effects, although additional factors may also contribute. Conclusions: [11C]Suzetrigine exhibits high affinity, good brain uptake, and selective target engagement in vitro, supporting its potential as a first-in-class NaV1.8-PET tracer. However, in vivo performance is confounded by P-gp-mediated efflux and possibly other mechanisms that limit accurate quantification of NaV1.8 in the living brain. These findings underscore the critical role of efflux transporters in CNS radiotracer development and highlight the need for design strategies that mitigate P-gp interaction when targeting ion channels in the brain. Future studies will include imaging under constant P-gp inhibition, arterial blood sampling for radiometabolite analysis and full kinetic modeling, and evaluation in non-human primates to assess translational feasibility.
- 28 November 2025
- Published by MDPI AG in Pharmaceuticals
- Vol. 18 (12) , 1816
Open AccessToward Brain NaV1.8 Imaging with [11C]Suzetrigine
Background/Objective: Acute and chronic pain affect millions of individuals, yet there are currently no molecular imaging tools to directly assess pain-related mechanisms in the central nervous system (CNS). The voltage-gated sodium channel NaV1.8 plays a pivotal role in neuropathic pain by increasing the excitability of nociceptive neurons following nerve injury or inflammation. In this work, we aimed to develop a novel positron emission tomography (PET) imaging probe for NaV1.8 to facilitate noninvasive quantification of this target in the CNS and thereby advance our understanding of pain neurobiology. Methods: We selected the compound suzetrigine, a U.S. FDA-approved, highly selective non-opioid NaV1.8 inhibitor, as the first candidate for a NaV1.8-targeted PET tracer. The compound was first assessed using in silico docking and CNS multiparameter optimization (MPO) analysis to evaluate target binding and predicted brain penetrability. Radiolabeling was accomplished by O-methylation with [11C]methyl iodide to yield [11C]suzetrigine without structural modification. The tracer was then evaluated using in vitro binding assays, including autoradiography and saturation binding on rat brain tissues, to determine binding parameters (KD, Bmax), and using in vivo PET imaging in rats to assess brain uptake, time–activity curves (TACs), and tracer behavior under baseline and pretreatment conditions. Pretreatment was performed with unlabeled suzetrigine, the P-glycoprotein (P-gp) inhibitor verapamil, and the heterologous NaV1.8 inhibitor A-803467. Results: In silico docking demonstrated favorable binding of suzetrigine to the NaV1.8 active site, and the calculated CNS MPO score (>3.5) suggested adequate brain penetration. Radiochemical synthesis of [11C]suzetrigine via O-methylation yielded a high decay-corrected radiochemical yield (19.2 ± 2.7%, n = 3), excellent purity (>98%, n = 3), and moderate molar activity (62.9 ± 51.8 MBq/nmol, n = 3). Autoradiography on rat brain tissue confirmed saturable and selective binding of [11C]suzetrigine to NaV1.8. Saturation binding assays revealed a Bmax = 93 fmol/mg and a KD = 0.1 nM, supporting the imageability of NaV1.8 in the brain using this tracer. In vivo PET imaging in rats demonstrated rapid and sufficient brain uptake but revealed unexpected tracer behavior: signal intensity markedly increased following pretreatment with either unlabeled suzetrigine or the P-gp inhibitor verapamil, and showed a slight increase after pretreatment with the heterologous NaV1.8 inhibitor A-803467. Detailed analysis of PET images, TACs, and normalized area-under-curve (AUC) values indicated that these atypical uptake patterns were primarily attributable to P-gp-mediated effects, although additional factors may also contribute. Conclusions: [11C]Suzetrigine exhibits high affinity, good brain uptake, and selective target engagement in vitro, supporting its potential as a first-in-class NaV1.8-PET tracer. However, in vivo performance is confounded by P-gp-mediated efflux and possibly other mechanisms that limit accurate quantification of NaV1.8 in the living brain. These findings underscore the critical role of efflux transporters in CNS radiotracer development and highlight the need for design strategies that mitigate P-gp interaction when targeting ion channels in the brain. Future studies will include imaging under constant P-gp inhibition, arterial blood sampling for radiometabolite analysis and full kinetic modeling, and evaluation in non-human primates to assess translational feasibility.
- Open Access
- 30 December 2024
- Published by Springer Nature in Nature Communications
- Vol. 15 (1) , 1-15
Peripheral contributions to resting state brain dynamics
The correlational structure of brain activity dynamics in the absence of stimuli or behavior is often taken to reveal intrinsic properties of neural function. To test the limits of this assumption, we analyzed peripheral contributions to resting state activity measured by fMRI in unanesthetized, chemically immobilized male rats that emulate human neuroimaging conditions. We find that perturbation of somatosensory input channels modifies correlation strengths that relate somatosensory areas both to one another and to higher-order brain regions, despite the absence of ostensible stimuli or movements. Resting state effects are mediated by the same peripheral and thalamic structures that relay responses to overt sensory stimuli. The impact of basal peripheral input is reduced in a rat model of autism, which displays both lower somatosensory functional connectivity and insensitivity to vibrissa inactivation. These results demonstrate the influence of extrinsic influences on resting state brain phenotypes in health and disease.
- 30 December 2024
- Published by Springer Nature in Nature Communications
- Vol. 15 (1) , 1-15
Open AccessPeripheral contributions to resting state brain dynamics
The correlational structure of brain activity dynamics in the absence of stimuli or behavior is often taken to reveal intrinsic properties of neural function. To test the limits of this assumption, we analyzed peripheral contributions to resting state activity measured by fMRI in unanesthetized, chemically immobilized male rats that emulate human neuroimaging conditions. We find that perturbation of somatosensory input channels modifies correlation strengths that relate somatosensory areas both to one another and to higher-order brain regions, despite the absence of ostensible stimuli or movements. Resting state effects are mediated by the same peripheral and thalamic structures that relay responses to overt sensory stimuli. The impact of basal peripheral input is reduced in a rat model of autism, which displays both lower somatosensory functional connectivity and insensitivity to vibrissa inactivation. These results demonstrate the influence of extrinsic influences on resting state brain phenotypes in health and disease.